Nanologica AB (publ) (FRA:4YD)

Market Cap	13.09M +11.9%
Revenue (ttm)	2.90M +57.2%
Net Income	2.19M
EPS	0.02
Shares Out	n/a
PE Ratio	5.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0260
Previous Close	0.0298
Day's Range	0.0260 - 0.0260
52-Week Range	0.0020 - 0.1250
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Nanologica AB

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides; NLAB Idun SP, a strong cation exchanger with...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 72
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4YD

Financial Performance

In 2025, Nanologica AB's revenue was 21.13 million, an increase of 45.32% compared to the previous year's 14.54 million. Losses were -51.29 million, -21.85% less than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error